Avelumab May Benefit Some Patients With Advanced Unresectable Mesothelioma Avelumab May Benefit Some Patients With Advanced Unresectable Mesothelioma

The anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody avelumab is well tolerated and shows antitumor activity in some patients with previously treated unresectable mesothelioma, according to results from a single-arm trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news